Pharmaceutical composition for preventing or treating refractory bone defects

The combination of human dental pulp stem cells and a porous scaffold material addresses the challenge of intractable bone defects by inducing bone regeneration and angiogenesis, effectively treating delayed healing and osteonecrosis in elderly patients with impaired bone healing.

WO2024237186A1PCT designated stage expired Publication Date: 2024-11-21HOKKAIDO UNIVERSITY +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017369
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for intractable bone defects, such as delayed healing and osteonecrosis, are inadequate as they often fail to effectively regenerate bone tissue and restore the natural healing process, especially in elderly individuals with decreased stem cell numbers or osteoporosis.

Method used

A pharmaceutical composition combining human dental pulp stem cells with a porous scaffold material having osteoinductive ability, specifically using calcium phosphates, collagen, and bioabsorbable polymers, to promote bone regeneration and angiogenesis in bone defect areas.

Benefits of technology

The composition significantly enhances bone tissue regeneration and healing in intractable bone defects by differentiating stem cells into osteoblasts and promoting angiogenesis, effectively treating delayed healing and osteonecrosis, even in elderly patients with impaired bone healing mechanisms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017369_21112024_PF_FP_ABST
    Figure JP2024017369_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention pertains to a pharmaceutical composition for preventing or treating refractory bone defects, the pharmaceutical composition comprising: human dental pulp stem cells; and a porous scaffold material having bone-inducing ability. Preferably, the human dental pulp stem cells are cultured together with the scaffold material, and are applied to a bone defect part to assist in the regeneration of bone tissue containing cancellous bone.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for preventing or treating intractable bone defects

[0001] Related Applications: This specification includes the contents of the specification of Japanese Patent Application No. 2023-78990 (filed May 12, 2023), which is the basis of the priority of this application. Technical Field: The present invention relates to a pharmaceutical composition for preventing or treating intractable bone defects, which comprises human dental pulp stem cells and a porous scaffold with osteoinductive ability, and bone tissue regeneration using said composition.

[0002] When a bone fracture occurs in the body, a stepwise repair process occurs at the site of injury (bone defect): hematoma formation, callus formation, callus sclerosis, bone tissue differentiation, and remodeling. This is the body's inherent bone regeneration mechanism, and the progress of healing varies depending on the severity of injury, the fracture site, the patient's age, physique, and lifestyle. A significantly delayed healing process is medically known as delayed union, and bones in this delayed healing state often undergo a halt, resulting in the formation of a nonunion. Elderly individuals are prone to delayed healing and nonunion due to a decrease in the number of stem cells in the bone marrow or periosteum, a decrease in the proliferation and differentiation capacity of stem cells, or osteoporosis. This delayed healing and transition to nonunion are also referred to as intractable fractures. Furthermore, avascular necrosis in specific bone tissue, which does not result in a repair and regeneration response, is called osteonecrosis, and is a typical intractable bone disease that causes pathological fractures. In such intractable fractures or osteonecrosis, the bone's natural healing ability does not function, resulting in intractable bone defects.

[0003] Treatment for intractable bone defects is selected according to the patient's condition, including revision surgery, bone grafting, and implantation of bioabsorbable polymers or bone substitute materials. Recently, attempts have been made to apply regenerative medicine to the treatment of intractable bone defects.

[0004] Stem cells derived from human dental pulp (dental pulp stem cells) have been reported to be effective in treating spinal cord injury, cerebral palsy (perinatal hypoxic-ischemic encephalopathy), and lower limb ischemia in animal model experiments. One study reported that bone regeneration was observed when human deciduous dental pulp stem cells (SHED) were transplanted together with hydroxyapatite-collagen sponge into alveolar bone defects in children with cleft lip and palate (Non-Patent Document 1). Other studies reported bone regeneration when dental pulp stem cells were transplanted together with bone substitute material into calvarial bone defects in rabbits and mice (Non-Patent Documents 2 and 3). However, cleft lip and palate is caused by congenital poor fusion of facial tissues, such as the soft and hard palate, and is different from acquired, intractable bone defects. Furthermore, the skull is richer in cortical bone than cancellous bone, and therefore does not reflect the bone defects in long bones such as the femur or vertebral bones. Furthermore, Non-Patent Documents 2 and 3 state that osteoprogenitor cells are present in the defect area of ​​the skull and that the body's repair mechanism is functioning, and do not reflect an intractable bone defect state.

[0005] Tanikawa et al., Stem Cells Int. 2020 Mar 12;2020:6234167. doi: 10.1155 / 2020 / 6234167.Lee et al., Int J Mol Sci. 2019 Oct; 20(20): 5015. doi: 10.3390 / ijms20205015Putranti et al., Cells 2022, 11, 1914. doi: 10.3390 / cells11121914

[0006] An object of the present invention is to provide a novel method for treating primarily acquired, intractable bone defects.

[0007] The inventors created an animal model that mimicked intractable bone defects and discovered that by transplanting a porous scaffold with bone induction ability together with human dental pulp stem cells into the animal model, the bone tissue healing effect of existing scaffolds can be significantly improved.

[0008] The present invention is based on the above findings, and in a first aspect provides the following [1] to

[22] . [1] A pharmaceutical composition for preventing or treating intractable bone defects, comprising human dental pulp stem cells and a porous scaffold having osteoinductive ability. [2] The pharmaceutical composition according to [1], wherein the human dental pulp stem cells are human deciduous tooth pulp stem cells. [3] The pharmaceutical composition according to [1] or [2], wherein the scaffold is biodegradable. [4] The pharmaceutical composition according to any of [1] to [3], wherein the scaffold is composed of any one selected from calcium phosphates, collagen, bioabsorbable polymers, glucosamines, demineralized bone, and a complex consisting of two or more of these. [5] The pharmaceutical composition according to [4], wherein the calcium phosphates are one or a combination of two or more selected from the group consisting of dicalcium phosphate, tricalcium phosphate, tetracalcium phosphate, octacalcium phosphate, hydroxyapatite, carbonate apatite, and fluoroapatite; the collagen is one or a combination of two or more selected from the group consisting of type I collagen, type II collagen, type III collagen, and synthetic collagen; the bioabsorbable polymer is one or a combination of two or more selected from the group consisting of polylactic acid polymer, polyglycolic acid polymer, and polylactic acid / glycolic acid polymer; the glucosamines are glucosamine, N-acetylglucosamine, or a combination thereof; and the demineralized bone is derived from mammalian bone. [6] The pharmaceutical composition according to any of [1] to [5] below, wherein the scaffold material [6a] or [6b] [6a] has a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [6b] The pharmaceutical composition according to any one of [1] to [5], wherein the scaffold has a porosity of 50% or more and a pore size of 20 to 700 μm, more preferably a porosity of 70% or more and a pore size of 50 to 600 μm, and even more preferably a porosity of 90% or more and a pore size of 100 to 500 μm. [7] The pharmaceutical composition according to any one of [1] to [6], wherein the scaffold has a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm.[8] The pharmaceutical composition according to any one of [1] to [7], wherein the scaffold material is composed of any one selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0, collagen, and a complex consisting of two or more of these substances. [8b] The pharmaceutical composition according to any one of [1] to [7], wherein the scaffold material is composed of a complex consisting of collagen and one or two substances selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0. [9] The pharmaceutical composition according to any one of [1] to [8], wherein the scaffold material is composed of any one selected from hydroxyapatite, β-TCP, collagen, and a complex consisting of two or more of these substances. [9b] ​​The pharmaceutical composition according to any one of [1] to [8], wherein the scaffold material is composed of a complex consisting of hydroxyapatite and / or β-TCP and collagen.

[10] The pharmaceutical composition according to any one of [1] to [9], wherein the scaffold material is a complex consisting of hydroxyapatite and collagen.

[0009]

[11] The pharmaceutical composition according to

[11] , wherein the scaffold comprises hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, as set forth below in [11a], [11b], [11c], or [11d]. [11a] The pharmaceutical composition according to

[11] , wherein the scaffold is a composite of hydroxyapatite and collagen, comprising hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, with a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm, and a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [11b] The pharmaceutical composition according to

[12] , wherein the scaffold is a composite of hydroxyapatite and collagen, comprising hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, with a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm, and with a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [11c] The pharmaceutical composition according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, containing hydroxyapatite and collagen in a weight ratio of 90:10 to 80:20, having a pore size of 100 to 500 μm, and having a porosity of 90% or more. [11d] The pharmaceutical composition according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, containing hydroxyapatite and collagen in a weight ratio of 80:20, having a pore size of 100 to 500 μm, and having a porosity of 90% or more.

[12] The pharmaceutical composition according to any of [1] to

[11] , wherein the pharmaceutical composition is prepared by culturing human dental pulp stem cells together with the scaffold.

[13] The following [13a], [13b], or [13c] [13a] Scaffold 100mm 3 1x10 per 4 cells or more, preferably 5 x 10 4 cells or more, preferably 1x10 5 cells or more, preferably 2x10 5 cells or more, preferably 5x10 5 cells or more, particularly preferably 1x10 6 cells or more, e.g., 1x10 5 ~1x10 6[13b] The pharmaceutical composition according to any one of [1] to

[12] , wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, and the scaffold is 100 mm 3 At least 1x10 per 4 [13c] The pharmaceutical composition according to any one of [1] to

[12] , wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, the porosity being 90% or more, and the scaffold is 100 mm 3 At least 1x10 per 4

[14] The pharmaceutical composition according to any one of [1] to

[12] , comprising at least 100 cells of human dental pulp stem cells.

[14] The pharmaceutical composition according to any one of [1] to

[13] , wherein the refractory bone defect is selected from the group consisting of femoral fracture, vertebral fracture including vertebral compression fracture, hip fracture, limb fracture, osteonecrosis of the femoral head, and pelvic fracture. [14b] The pharmaceutical composition according to any one of [1] to

[13] , wherein the refractory bone defect is caused by impaired angiogenesis that impairs the natural bone healing mechanism. [14c] The pharmaceutical composition according to any one of [1] to

[13] , wherein the refractory bone defect is selected from Kienböck's disease, osteonecrosis of the carpal tunnel syndrome, osteonecrosis of the femoral head, osteonecrosis of the talus, Perthes' disease, Sever's disease, Köhler's disease, Freiberg's disease, and second Köhler's disease. [14d] The pharmaceutical composition according to any one of [1] to

[13] , wherein the intractable bone defect is caused by a drug, alcohol intake, or radiation exposure.

[15] The pharmaceutical composition according to any one of [1] to

[14] , wherein the prevention or treatment of the intractable bone defect is prevention or treatment of delayed healing, prevention or treatment of osteonecrosis, or prevention of pseudoarthrosis.

[16] The pharmaceutical composition according to any one of [1] to

[15] , wherein the pharmaceutical composition regenerates bone tissue including cancellous bone in a bone defect site, or wherein the intractable bone defect is treated or prevented by regenerating bone tissue including cancellous bone in a bone defect site.

[17] The pharmaceutical composition according to any one of [1] to

[15] , wherein the pharmaceutical composition regenerates bone tissue accompanied by angiogenesis in a bone defect site, or wherein the pharmaceutical composition treats or prevents intractable bone defect by regenerating bone tissue accompanied by angiogenesis in a bone defect site.

[18] The pharmaceutical composition according to any one of [1] to

[17] , wherein the pharmaceutical composition is administered to a human.

[19] The pharmaceutical composition according to

[18] , wherein the human is an elderly person aged 65 years or older.

[20] The pharmaceutical composition of

[18] , wherein the human has been diagnosed with osteoporosis.

[21] The pharmaceutical composition of

[18] , wherein the human has been diagnosed with osteonecrosis of the femoral head.

[22] The pharmaceutical composition of

[18] , wherein the human has a decreased number of osteoprogenitor cells or a decreased proliferation or differentiation ability in a bone defect site.

[0010] In a second aspect, the present invention provides the following [1] to

[22] . [1] A composition comprising human dental pulp stem cells and a porous scaffold with osteoinductive ability, for use in the prevention or treatment of intractable bone defects. [2] The composition for use according to [1], wherein the human dental pulp stem cells are human deciduous tooth pulp stem cells. [3] The composition for use according to [1] or [2], wherein the scaffold is biodegradable. [4] The composition for use according to any of [1] to [3], wherein the scaffold is composed of any one selected from calcium phosphates, collagen, bioabsorbable polymers, glucosamines, demineralized bone, and a composite consisting of two or more of these. [5] The calcium phosphates are one or a combination of two or more selected from the group consisting of dicalcium phosphate, tricalcium phosphate, tetracalcium phosphate, octacalcium phosphate, hydroxyapatite, carbonate apatite, and fluoroapatite; the collagen is one or a combination of two or more selected from the group consisting of type I collagen, type II collagen, type III collagen, and synthetic collagen; the bioabsorbable polymer is one or a combination of two or more selected from the group consisting of polylactic acid polymer, polyglycolic acid polymer, and polylactic acid / glycolic acid polymer; the glucosamines are glucosamine, N-acetylglucosamine, or a combination thereof; the demineralized bone is derived from mammalian bone; [6] The composition for use according to any of [1] to [5] below, wherein the scaffold material [6a] or [6b] [6a] has a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [6b] The composition for use according to any one of [1] to [5], wherein the scaffold has a porosity of 50% or more and a pore size of 20 to 700 μm, more preferably a porosity of 70% or more and a pore size of 50 to 600 μm, and even more preferably a porosity of 90% or more and a pore size of 100 to 500 μm. [7] The composition for use according to any one of [1] to [6], wherein the scaffold has a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm.[8] The composition for use according to any one of [1] to [7] below, [8a] or [8b]. [8a] The composition for use according to any one of [1] to [7], wherein the scaffold material is composed of a substance selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0, collagen, and a complex consisting of two or more of these. [8b] The composition for use according to any one of [1] to [7], wherein the scaffold material is composed of a complex consisting of collagen and one or two substances selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0. [9] The composition for use according to any one of [1] to [8] below, [9a] or [9b]. [9a] The composition for use according to any one of [1] to [8], wherein the scaffold material is composed of a substance selected from hydroxyapatite, β-TCP, collagen, and a complex consisting of two or more of these. [9b] ​​The composition for use according to any one of [1] to [8], wherein the scaffold material is composed of a complex consisting of hydroxyapatite and / or β-TCP and collagen.

[10] The composition for use according to any one of [1] to [9], wherein the scaffold material is a complex consisting of hydroxyapatite and collagen.

[0011]

[11] The composition for use according to

[10] , wherein the scaffold comprises hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, as set forth below in [11a], [11b], [11c], or [11d]. [11a] The composition for use according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, comprising hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, with a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm, and a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [11c] The composition for use according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 90:10 to 80:20, the pore size being 100 to 500 μm, and the porosity being 90% or more. [11d] The composition for use according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, the pore size being 100 to 500 μm, and the porosity being 90% or more.

[12] The composition for use according to any of [1] to

[11] , wherein the composition is prepared by culturing human dental pulp stem cells together with the scaffold.

[13] The composition for use according to [13a], [13b], or [13c] below. [13a] Scaffold 100mm 3 1x10 per 4 cells or more, preferably 5 x 10 4 cells or more, preferably 1x10 5 cells or more, preferably 2x10 5 cells or more, preferably 5x10 5 cells or more, particularly preferably 1x10 6 cells or more, e.g., 1x10 5 ~1x10 6[13b] A composition for use according to any one of [1] to

[12] , containing human dental pulp stem cells. [13b] A scaffold material is a composite of hydroxyapatite and collagen, containing hydroxyapatite and collagen in a weight ratio of 80:20, and the scaffold material is 100 mm 3 At least 1x10 per 4 [13c] A composition for use according to any one of [1] to

[12] , comprising human dental pulp stem cells or more. [13c] A scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, the porosity being 90% or more, and the scaffold is 3 At least 1x10 per 4

[14] The composition for use according to any one of [1] to

[12] , comprising at least 100 cells of human dental pulp stem cells.

[14] The composition for use according to any one of [1] to

[13] , wherein the refractory bone defect is selected from femur fracture, vertebral fracture including vertebral compression fracture, hip fracture, limb fracture, osteonecrosis of the femoral head, and pelvic fracture. [14b] The composition for use according to any one of [1] to

[13] , wherein the refractory bone defect is caused by impaired angiogenesis that impairs the natural bone healing mechanism. [14c] The composition for use according to any one of [1] to

[13] , wherein the refractory bone defect is selected from Kienböck's disease, osteonecrosis of the carpal tunnel syndrome, osteonecrosis of the femoral head, osteonecrosis of the talus, Perthes' disease, Sever's disease, Köhler's disease, Freiberg's disease, and second Köhler's disease. [14d] The composition for use according to any one of [1] to

[13] , wherein the intractable bone defect is caused by drugs, alcohol consumption, or radiation exposure.

[15] The composition for use according to any one of [1] to

[14] , wherein the prevention or treatment of the intractable bone defect is the prevention or treatment of delayed healing or the prevention of false joint.

[16] The composition for use according to any one of [1] to

[15] , wherein the composition regenerates bone tissue including cancellous bone in a bone defect, or wherein the intractable bone defect is treated or prevented by regenerating bone tissue including cancellous bone in a bone defect.

[17] The composition for use according to any one of [1] to

[15] , wherein the composition regenerates bone tissue accompanied by angiogenesis in a bone defect, or wherein the composition treats or prevents intractable bone defects by regenerating bone tissue accompanied by angiogenesis in a bone defect.

[18] The composition for use according to any one of [1] to

[17] , wherein the composition is administered to a human.

[19] The composition for use according to

[18] , wherein the human is an elderly person aged 65 or older.

[20] The composition for use according to

[18] , wherein the human has been diagnosed with osteoporosis.

[21] The composition for use according to

[18] , wherein the human has been diagnosed with femoral head necrosis.

[22] The composition for use according to

[18] , wherein the human has a decreased number of osteoprogenitor cells or a decreased proliferation or differentiation ability in a bone defect site.

[0012] In a third aspect, the present invention provides the following [1] to

[24] . [1] A method for preventing or treating intractable bone defects, comprising administering human dental pulp stem cells and a porous scaffold having osteoinductive ability to a subject. [2] The method according to [1], wherein the human dental pulp stem cells are human deciduous tooth pulp stem cells. [3] The method according to [1], wherein the scaffold is biodegradable. [4] The method according to [1], wherein the scaffold is composed of any one selected from calcium phosphates, collagen, bioabsorbable polymers, glucosamines, demineralized bone, and a complex consisting of two or more of these. [5] The calcium phosphates are one or a combination of two or more selected from the group consisting of dicalcium phosphate, tricalcium phosphate, tetracalcium phosphate, octacalcium phosphate, hydroxyapatite, carbonate apatite, and fluoroapatite; the collagen is one or a combination of two or more selected from the group consisting of type I collagen, type II collagen, type III collagen, and synthetic collagen; the bioabsorbable polymer is one or a combination of two or more selected from the group consisting of polylactic acid polymer, polyglycolic acid polymer, and polylactic acid / glycolic acid polymer; the glucosamines are glucosamine, N-acetylglucosamine, or a combination thereof; the demineralized bone is derived from mammalian bone; [6] The method according to [1], wherein the scaffold has a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [6b] The method according to [1], wherein the scaffold has a porosity of 50% or more and a pore size of 20 to 700 μm, more preferably a porosity of 70% or more and a pore size of 50 to 600 μm, and even more preferably a porosity of 90% or more and a pore size of 100 to 500 μm. [7] The method according to [1], wherein the scaffold has a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm. [8] [8a] or [8b] below. [8a] The method according to [1], wherein the scaffold is composed of any one selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0, collagen, and a complex consisting of two or more of these.[8b] The method according to [1], wherein the scaffold is composed of a complex of collagen and one or two substances selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0. [9] The method according to [1], wherein the scaffold is composed of any one selected from the group consisting of [9a] or [9b] ​​below. [9a] The method according to [1], wherein the scaffold is composed of hydroxyapatite, β-TCP, collagen, and complexes consisting of two or more of these. [9b] ​​The method according to [1], wherein the scaffold is composed of a complex of hydroxyapatite and / or β-TCP and collagen.

[10] The method according to [1], wherein the scaffold is a complex of hydroxyapatite and collagen.

[0013]

[11] The method according to

[10] , wherein the scaffold comprises hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20. [11b] The method according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, the composite comprising hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, and having a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm, and a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [11c] The method according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, containing hydroxyapatite and collagen in a weight ratio of 90:10 to 80:20, having a pore size of 100 to 500 μm, and having a porosity of 90% or more. [11d] The method according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, containing hydroxyapatite and collagen in a weight ratio of 80:20, having a pore size of 100 to 500 μm, and having a porosity of 90% or more.

[12] The method according to [1], comprising a step of culturing human dental pulp stem cells together with the scaffold before administration to the subject.

[13] The method according to [13a], [13b], or [13c] below. [13a] Scaffold 100mm3 1x10 per 4 cells or more, preferably 5 x 10 4 cells or more, preferably 1x10 5 cells or more, preferably 2x10 5 cells or more, preferably 5x10 5 cells or more, particularly preferably 1x10 6 cells or more, e.g., 1x10 5 ~1x10 6 [13b] The method according to [1], wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, and the scaffold is 100 mm thick. 3 At least 1x10 per 4 [13c] The method according to [1], wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, the porosity being 90% or more, and the scaffold is 100 mm 3 At least 1x10 per 4The method of [1], in which at least 100 cells of human dental pulp stem cells are administered.

[14] The method of [1], in which the following [14a], [14b], [14c], or [14d] is selected from the group consisting of: [14a], [14b], [14c], and [14d]. [14a] The method of [1], in which the refractory bone defect is any one selected from femur fracture, vertebral fracture including vertebral compression fracture, hip fracture, limb fracture, osteonecrosis of the femoral head, and pelvic fracture. [14b] The method of [1], in which the refractory bone defect is caused by impaired natural bone healing mechanism due to impaired angiogenesis. [14c] The method of [1], in which the refractory bone defect is any one selected from Kienböck's disease, osteonecrosis of the carpal tunnel syndrome, osteonecrosis of the femoral head, osteonecrosis of the talus, Perthes' disease, Sever's disease, Köhler's disease, Freiberg's disease, and second Köhler's disease. [14d] The method of [1], in which the refractory bone defect is caused by a drug, alcohol intake, or radiation exposure.

[15] The method according to [1], wherein the prevention or treatment of refractory bone defects is prevention or treatment of delayed healing, prevention or treatment of osteonecrosis, or prevention of pseudoarthrosis.

[16] The method according to [1], wherein regeneration of bone tissue including cancellous bone is effected in a bone defect, or the treatment or prevention of refractory bone defects is effected by regenerating bone tissue including cancellous bone in a bone defect.

[17] The method according to [1], wherein regeneration of bone tissue accompanied by angiogenesis is effected in a bone defect, or the treatment or prevention of refractory bone defects is effected by regenerating bone tissue accompanied by angiogenesis in a bone defect.

[18] The method according to [1], wherein the subject is a human.

[19] The method according to

[18] , wherein the human is 65 years of age or older.

[20] The method according to

[18] , wherein the human has been diagnosed with osteoporosis.

[21] The method according to

[18] , wherein the human has been diagnosed with femoral head necrosis.

[22] The method according to

[18] , wherein the human has a reduced number of osteoprogenitor cells or a reduced proliferation or differentiation ability in a bone defect.

[23] A method for regenerating bone tissue including cancellous bone in an intractable bone defect, comprising administering to a subject human dental pulp stem cells and a porous scaffold having osteoinductive ability.

[24] A method for regenerating bone tissue with angiogenesis in an intractable bone defect, comprising administering to a subject human dental pulp stem cells and a porous scaffold having osteoinductive ability.

[0014] In a fourth aspect, the present invention provides the following [1] to

[22] . [1] Use of human dental pulp stem cells and a porous scaffold having osteoinductive ability in the manufacture of a pharmaceutical composition for preventing or treating intractable bone defects. [2] The use according to [1], wherein the human dental pulp stem cells are human deciduous tooth pulp stem cells. [3] The use according to [1] or [2], wherein the scaffold is biodegradable. [4] The use according to any of [1] to [3], wherein the scaffold is composed of any one selected from calcium phosphates, collagen, bioabsorbable polymers, glucosamines, demineralized bone, and complexes consisting of two or more of these. [5] The use according to [4], wherein the calcium phosphates are one or a combination of two or more selected from the group consisting of dicalcium phosphate, tricalcium phosphate, tetracalcium phosphate, octacalcium phosphate, hydroxyapatite, carbonate apatite, and fluoroapatite; the collagen is one or a combination of two or more selected from the group consisting of type I collagen, type II collagen, type III collagen, and synthetic collagen; the bioabsorbable polymer is one or a combination of two or more selected from the group consisting of polylactic acid polymer, polyglycolic acid polymer, and polylactic acid / glycolic acid polymer; the glucosamines are glucosamine, N-acetylglucosamine, or a combination thereof; and the demineralized bone is derived from mammalian bone. [6] The use according to any of [1] to [5] below [6a] or [6b] [6a], wherein the scaffold has a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [6b] The use according to any one of [1] to [5], wherein the scaffold has a porosity of 50% or more and a pore size of 20 to 700 μm, more preferably a porosity of 70% or more and a pore size of 50 to 600 μm, and even more preferably a porosity of 90% or more and a pore size of 100 to 500 μm. [7] The use according to any one of [1] to [6], wherein the scaffold has a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm.[8] The use according to any one of [1] to [7] below, [8a] or [8b] [8a], wherein the scaffold material is composed of any one selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0, collagen, and a complex consisting of two or more of these. [8b] The use according to any one of [1] to [7] below, [8a] or [8b] [8a], wherein the scaffold material is composed of a complex consisting of collagen and one or two substances selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0. [9] The use according to any one of [1] to [8] below, [9a] or [9b] ​​[9a], wherein the scaffold material is composed of any one selected from hydroxyapatite, β-TCP, collagen, and a complex consisting of two or more of these. [9b ...10] The use according to any one of [1] to [9] below,

[10] , wherein the scaffold material is a complex consisting of hydroxyapatite and collagen.

[0015]

[11] The use according to

[11] , wherein the scaffold comprises hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, as set forth below in [11a], [11b], [11c], or [11d]. [11a] The use according to

[11] , wherein the scaffold is a composite of hydroxyapatite and collagen, comprising hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, with a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm, and a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [11b] The use according to

[12] , wherein the scaffold is a composite of hydroxyapatite and collagen, comprising hydroxyapatite and collagen in a weight ratio of 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20, with a pore size of 20 to 700 μm, preferably 50 to 600 μm, and more preferably 100 to 500 μm, and with a porosity of 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more. [11c] The use according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, containing hydroxyapatite and collagen in a weight ratio of 90:10 to 80:20, having a pore size of 100 to 500 μm, and having a porosity of 90% or more. [11d] The use according to

[10] , wherein the scaffold is a composite of hydroxyapatite and collagen, containing hydroxyapatite and collagen in a weight ratio of 80:20, having a pore size of 100 to 500 μm, and having a porosity of 90% or more.

[12] The use according to any of [1] to

[11] , wherein the pharmaceutical composition is prepared by culturing human dental pulp stem cells together with the scaffold.

[13] The use according to any of [13a], [13b], or [13c] below. [13a] The pharmaceutical composition is prepared by culturing human dental pulp stem cells together with the scaffold. 3 1x10 per 4 cells or more, preferably 5 x 10 4 cells or more, preferably 1x10 5 cells or more, preferably 2x10 5 cells or more, preferably 5x10 5 cells or more, particularly preferably 1x10 6 cells or more, e.g., 1x10 5 ~1x10 6[13b] The use according to any one of [1] to

[12] , wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, and the scaffold is 100 mm 3 At least 1x10 per 4 [13c] The use according to any one of [1] to

[12] , wherein the scaffold is a composite of hydroxyapatite and collagen, the hydroxyapatite and collagen being contained in a weight ratio of 80:20, the porosity being 90% or more, and the scaffold is 100 mm 3 At least 1x10 per 4The use according to any one of [1] to

[12] , wherein the refractory bone defect is selected from femur fracture, vertebral fracture including vertebral compression fracture, hip fracture, limb fracture, osteonecrosis of the femoral head, and pelvic fracture. [14b] The use according to any one of [1] to

[13] , wherein the refractory bone defect is caused by impaired angiogenesis that impairs the natural bone healing mechanism. [14c] The use according to any one of [1] to

[13] , wherein the refractory bone defect is selected from Kienböck's disease, osteonecrosis of the carpal tunnel syndrome, osteonecrosis of the femoral head, osteonecrosis of the talus, Perthes' disease, Sever's disease, Köhler's disease, Freiberg's disease, and second Köhler's disease. [14d] The use according to any one of [1] to

[13] , wherein the refractory bone defect is caused by drugs, alcohol consumption, or radiation exposure.

[15] The use according to any one of [1] to

[14] , wherein the prevention or treatment of refractory bone defect is the prevention or treatment of delayed healing or the prevention of false joint.

[16] The use according to any one of [1] to

[15] , wherein the pharmaceutical composition regenerates bone tissue, including cancellous bone, in a bone defect site, or treats or prevents refractory bone defects by regenerating bone tissue, including cancellous bone, in a bone defect site.

[17] The use according to any one of [1] to

[15] , wherein the pharmaceutical composition regenerates bone tissue, involving angiogenesis, in a bone defect site, or treats or prevents refractory bone defects by regenerating bone tissue, involving angiogenesis, in a bone defect site.

[18] The use according to any one of [1] to

[17] , wherein the pharmaceutical composition is administered to a human.

[19] The use according to

[18] , wherein the human is an elderly person aged 65 or older.

[20] The use according to

[18] , wherein the human has been diagnosed with osteoporosis.

[21] The use according to

[18] , wherein the human has been diagnosed with femoral head necrosis.

[22] The use according to

[17] , wherein the human has a decreased number of osteoprogenitor cells or a decreased proliferation or differentiation ability in a bone defect site.

[0016] The pharmaceutical composition of the present invention can regenerate bone tissue, including cancellous bone, and effectively prevent or treat intractable bone defects. Furthermore, the pharmaceutical composition of the present invention can enhance the expression of genes involved in angiogenesis at the bone defect site, thereby effectively preventing or treating intractable bone defects through the regeneration of bone tissue accompanied by angiogenesis.

[0017] Longitudinal observation of the bone repair process in the same individual using micro-CT. The top row shows 3D reconstructed micro-CT images of the left tibia (SHED: scaffold + SHED) and the bottom row shows the right tibia (Control: scaffold only). The bone hole coverage rate (repair rate) for each implantation group is shown. ■ Scaffold only, □ Scaffold + SHED HE-stained sections of the bone defect on the control side. a: Inside the proximal bone tunnel, b: Around ReFit in the center of the bone tunnel, c: Distal edge of the bone tunnel HE-stained sections of the bone defect on the scaffold + SHED side. a: Inside the proximal bone tunnel, b: Around ReFit in the center of the bone tunnel, c: Distal edge of the bone tunnel Number of cells in the scaffold 15 minutes after seeding with SHED. Number of cells in the scaffold 15 minutes and 1 hour after seeding with SHED. Observation of the bone repair process using micro-CT. 3D reconstructed micro-CT images of the transplanted side of SHED(-) and BMMSC(-): scaffold only, SHED: scaffold + SHED, BMMSC: scaffold + BMMSC. The bone hole coverage rate (repair rate) for each transplant group is shown. SHED: scaffold + SHED, BMMSC: scaffold + BMMSC, SHED(-) and BMMSC(-): scaffold only. Average bone hole coverage rate on the transplanted side.

[0018] 1. Pharmaceutical Composition The present invention relates to a pharmaceutical composition for preventing or treating intractable bone defects (hereinafter referred to as "the pharmaceutical composition of the present invention"), which comprises human dental pulp stem cells and a porous scaffold having osteoinductive ability.

[0019] "Human dental pulp stem cells" The human dental pulp stem cells of the present invention are genetically unmodified stem cells derived from human dental pulp. The "dental pulp" may be the dental pulp of either a baby tooth or a permanent tooth, but from the perspective of ease of acquisition, baby teeth or extracted teeth such as wisdom teeth are preferred, and baby teeth are more preferred.

[0020] The human dental pulp stem cells of the present invention may be autologous cells derived from the dental pulp of the recipient, or allogeneic cells derived from the dental pulp of another person. Preferably, the stem cells are allogeneic in terms of preparation time and cost, and the stability of cell quality.

[0021] Human dental pulp stem cells can be prepared by enzymatically isolating cells from human dental pulp (e.g., treatment with collagenase or collagenase and neutral protease) according to standard methods, culturing the cells, and obtaining a colony-forming cell population. The medium used preferably does not contain xenogeneic serum such as FBS, and serum-free medium is more preferred. Human dental pulp stem cells stored in stem cell banks may also be used if available.

[0022] The human dental pulp stem cells of the present invention are preferably CD73-positive, CD90-positive, and CD105-positive, and more preferably CD117-negative, CD73-positive, CD90-positive, and CD105-positive. Conventionally known dental pulp stem cells are either CD117-positive or a heterogeneous population containing CD117-positive and CD117-negative cells, but the dental pulp stem cells of the present invention are preferably a homogeneous CD117-negative cell population.

[0023] The human dental pulp stem cells of the present invention are preferably CD325-negative and preferably exhibit a CD49d and / or CD51 positivity rate of 90%, 95%, 97%, 98%, or 99% or higher. The dental pulp stem cells of the present invention are preferably CD31-, CD34-, and CD45-negative.

[0024] The human dental pulp stem cells of the present invention are preferably negative for HLA-DR, HLA-DQ, CD40, CD80, and CD86, which are involved in immunogenicity.

[0025] As used herein, a marker protein or marker gene being "positive" means that, when detected by techniques known in the art, the expression level of the protein or gene in a stem cell population is 30% or more, preferably 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, more preferably 90% or more, and in certain cases 91%, 92%, 93%, 94%, 95%, or 96% or more. A marker protein or marker gene being "negative" means that the expression level of the protein or gene in a stem cell population is less than 10%, preferably less than 7%, more preferably less than 6% or less than 5%.

[0026] Marker proteins can be detected by antibody-based immunoassays such as ELISA, immunostaining, and flow cytometry. In the case of proteins that are expressed intracellularly but not on the cell surface, the target protein can be detected by expressing a reporter protein together with the protein and detecting the reporter protein. Marker genes can be detected using nucleic acid amplification and / or nucleic acid detection methods such as RT-PCR, microarrays, and biochips.

[0027] For safety reasons, it is desirable that the human dental pulp stem cells used in the pharmaceutical composition of the present invention have undergone endotoxin testing, mycoplasma testing, sterility testing, and the like.

[0028] "Porous scaffold with osteoinductivity" The scaffold of the present invention is a porous scaffold with osteoinductivity. "Scaffold" refers to a material that serves as a scaffold for cells (or cell cultures), and a scaffold with "osteoinductivity" means that when the scaffold is implanted in a living body, it has the ability to induce bone formation by differentiating surrounding mesenchymal stem cells into osteoblasts. In the present invention, a porous scaffold with osteoinductivity and that allows cells to penetrate is used. When implanted into a bone defect in a living body (particularly preferably a fracture or osteonecrosis site), the osteoinductivity of the porous scaffold of the present invention induces bone formation by differentiating surrounding mesenchymal stem cells into osteoblasts, and it also functions as a scaffold for cells to form bone. When the scaffold is used in combination with human dental pulp stem cells, the pores of the scaffold also function as a scaffold for human dental pulp stem cells, and the human dental pulp stem cells can be encapsulated in the pores.

[0029] The "porous scaffolding material with bone induction ability" (hereinafter sometimes simply referred to as "scaffolding material") used in the present invention includes calcium phosphates, collagen, bioabsorbable polymers, glucosamines, demineralized bone, and composites of two or more of these.

[0030] Examples of calcium phosphates include dicalcium phosphate, tricalcium phosphate, tetracalcium phosphate, octacalcium phosphate, and apatites such as hydroxyapatite, carbonate apatite, fluoroapatite, etc. Among these, calcium phosphates with a Ca / P ratio of 1.0 to 2.0 are preferred, with hydroxyapatite being more preferred.

[0031] The collagen may be either natural collagen or synthetic collagen, but mammal-derived collagen (type I, type II, type III) or synthetic collagen is preferred, with mammal-derived type I collagen being more preferred.

[0032] Examples of bioabsorbable polymers include polylactic acid (PLA), polyglycolic acid (PGA), and polylactic-glycolic acid polymer (PLGA).

[0033] Glucosamines include glucosamine and N-acetylglucosamine. The demineralized bone is preferably demineralized bone derived from breast milk bones.

[0034] Any of the above materials may be a derivative having an appropriate modification, or may be a complex consisting of two or more of these materials.

[0035] Preferably, the scaffold is a composite of calcium phosphates and collagen, more preferably a composite of calcium phosphates and naturally occurring collagen with a Ca / P ratio of about 1.0 to 2.0, and particularly preferably a composite of hydroxyapatite and collagen (preferably mammalian type I collagen). The Ca / P ratio of calcium phosphates can be determined by quantifying the Ca ions (e.g., by atomic absorption spectrometry) and the P ions (e.g., by phosphomolybdic acid colorimetry) in the material.

[0036] When the scaffold is made of calcium phosphate and collagen, the weight ratio of calcium phosphate to collagen is 90:10 to 50:50, preferably 90:10 to 75:25, and more preferably 90:10 to 80:20.

[0037] The scaffold is porous, and the porosity is, for example, 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more.

[0038] The average pore size of the scaffold material is preferably 20 to 700 μm, more preferably 50 to 600 μm, and even more preferably 100 to 500 μm, so as to allow easy cell penetration.

[0039] Preferably, the scaffold has a porosity of 50% or more and a pore size of 20 to 700 μm, more preferably a porosity of 70% or more and a pore size of 50 to 600 μm, and even more preferably a porosity of 90% or more and a pore size of 100 to 500 μm.

[0040] Methods for producing materials with a porous structure are disclosed in, for example, Japanese Patent Application Laid-Open Nos. 07-291759, 2000-302567, 2009-132601, 2013-79172, and 2021-31352. A method for processing natural bone is disclosed in, for example, Japanese Patent Application Laid-Open No. H02-504627.

[0041] The scaffold may be a commercially available bone filler, bone regeneration material, etc. Examples of commercially available scaffolds include Grafton DBM (Medtronic), Bio-Oss (registered trademark) Collagen (Geistlich Pharma), Bonarc (registered trademark) (Toyobo Co., Ltd.), ReFit (registered trademark) (HOYA Technosurgical Corporation), and Ospherion (Olympus Corporation).

[0042] "Pharmaceutical composition" The pharmaceutical composition (or composition) of the present invention contains the above-mentioned human dental pulp stem cells and scaffold material. The ratio of scaffold material to human dental pulp stem cells is not limited, but is preferably 100 mm 3 Per 1x10 4 cells or more, preferably 5 x 10 4 cells or more, preferably 1x10 5 cells or more, preferably 2x10 5 cells or more, preferably 5x10 5 cells or more, particularly preferably 1x10 6 cells or more, e.g., 1x10 5 ~1x10 6 Contains cells.

[0043] The pharmaceutical composition of the present invention can be prepared by culturing human dental pulp stem cells with a scaffold before application to a subject. Therefore, the pharmaceutical composition of the present invention can contain a culture supernatant (culture product, culture solution) of human dental pulp stem cells. The method for preparing the pharmaceutical composition of the present invention will be described in detail in the next section.

[0044] The pharmaceutical composition of the present invention may be provided as a pharmaceutical composition containing human dental pulp stem cells and a scaffold material in advance, or may be provided as a kit containing human dental pulp stem cells (human dental pulp stem cell culture containing culture supernatant) and a scaffold material separately, which are combined before use. When the pharmaceutical composition of the present invention is provided as a kit, the human dental pulp stem cells are mixed with 100 mm of scaffold material. 3 At least 1x10 per 4 Alternatively, the human dental pulp stem cells and scaffold material in the kit can be mixed and cultured for 24 to 48 hours to form a 100 mm scaffold. 3 At least 1x10 per 4 Alternatively, the number of cells may be adjusted to provide the number of cells.

[0045] In addition to human dental pulp stem cells (human dental pulp stem cell cultures containing culture supernatants) and scaffolds, the pharmaceutical compositions of the present invention may contain pharmacologically acceptable carriers or vehicles, provided that the present invention is not adversely affected by the objectives of the present invention. Specifically, the pharmaceutical compositions of the present invention may contain sterilized water, physiological saline, culture media, physiological buffer solutions such as PBS, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, excipients, vehicles, preservatives, binders, etc. They may also contain cryopreservatives.

[0046] "Prevention or Treatment of Intractable Bone Defects" The pharmaceutical composition of the present invention is used to prevent or treat intractable bone defects. In the present invention, "intractable bone defects" refers to a state in which bone repair is delayed due to a decrease in the intrinsic healing ability at the fracture site, and includes states in which delayed healing and pseudoarthrosis are progressing. "Delayed healing" refers to a state in which the progress of fracture healing is significantly delayed, and "pseudoarthrosis" refers to a state in which the healing process is interrupted in a bone in a delayed healing state. Furthermore, "intractable bone defects" in the present invention also include osteonecrosis states in which avascular necrosis occurs in bone tissue and no repair or regeneration response occurs. Such intractable bone defects can occur due to impaired blood circulation, which impairs the natural bone healing function. In the present invention, "intractable bone defects" also include states in which sufficient effects are not observed with bone regeneration treatments such as ultrasound therapy at the fracture site or bone fillers or artificial bone implants.

[0047] In the present invention, "preventing or treating intractable bone defects" means promoting bone repair (bone fusion) at a fracture site where healing progress is delayed, preventing delayed healing at a fracture site, improving delayed healing at a fracture site, preventing osteonecrosis, promoting bone repair at an osteonecrotic site, or preventing pseudoarthrosis at a fracture site. Note that bone repair at a bone defect site includes regeneration of cancellous bone and / or regeneration of compact bone.

[0048] In the present invention, "refractory bone defect" refers to an acquired refractory fracture or osteonecrosis. Refractory fractures are not particularly limited, but are preferably fractures of bones other than the skull, preferably fractures of long bones or vertebral bones, and more preferably fractures extending to the cancellous bone portion of long bones or vertebral bones. Examples of such fractures include femoral fractures, vertebral fractures (including vertebral compression fractures), hip fractures, limb fractures, osteonecrosis of the femoral head, and pelvic fractures. Osteonecrosis includes, but is not limited to, osteonecrosis caused by drug or alcohol intake, radiation exposure or trauma, or idiopathic osteonecrosis. Examples of osteonecrosis in children include Perthes disease occurring in the proximal femoral epiphysis, Sever's disease occurring in the calcaneal epiphysis, Köhler's disease occurring in the navicular bone, and Freiberg or second Köhler's disease occurring in the metatarsal head, while in adults, Kienböck's disease occurring in the lunate bone, osteonecrosis of the navicular bone, osteonecrosis of the femoral head, and osteonecrosis of the talus.

[0049] The intractable bone defects of the present invention may be caused by any of trauma, fatigue, disease (e.g., caisson disease and bone metastasis of cancer, including idiopathic cases), drug side effects (e.g., bone resorption inhibitors and steroid drugs), and alcohol intake, but traumatic and pathological bone defects are preferred.

[0050] The method of application of the pharmaceutical composition of the present invention is appropriately determined depending on the state of fracture or osteonecrosis and the structure of the bone defect site, and may be either surgical implantation or percutaneous implantation. In percutaneous implantation, the composition can be applied as a mixture of cells and a scaffold crushed using a needle.

[0051] The pharmaceutical composition of the present invention may be implanted into the bone defect site either alone or together with surgical fixation.

[0052] 2. Method for preparing pharmaceutical composition The pharmaceutical composition of the present invention is prepared by adding human dental pulp bone stem cells to a scaffold and culturing them.

[0053] Examples of "media" used to culture human dental pulp osteoblasts include, but are not limited to, α-MEM medium, DMEM medium, BME medium, Eagle MEM medium, BGJb medium, CMRL 1066 medium, Glasgow MEM (GMEM) medium, Improved MEM Zinc Option medium, IMDM medium, Medium 199 medium, F-12 medium, DMEM / F12 medium, IMDM / F12 medium, Ham's medium, RPMI 1640 medium, Fischer's medium, or mixtures thereof, as well as commercially available serum-free media for mammalian cells, such as MesenCult-ACF (STEMCELL Technologies), STEMPRO MSC SFM (ThermoFischer Scientific), and UltraCULTURE Serum-free (Lonza). For clinical use, animal-free media are preferred, and xeno-free media (containing no xenogeneic components) are even more preferred.

[0054] The "culture medium" may contain various nutrients necessary for cell maintenance and proliferation and various components necessary for differentiation induction, as appropriate, within the scope of the present invention. For example, nutrient sources may include carbon sources such as glycerol, glucose, fructose, sucrose, lactose, honey, starch, and dextrin; hydrocarbons such as fatty acids, oils and fats, lecithin, and alcohols; nitrogen sources such as ammonium sulfate, ammonium nitrate, ammonium chloride, urea, and sodium nitrate; inorganic salts such as table salt, potassium salts, phosphates, magnesium salts, calcium salts, iron salts, and manganese salts; monopotassium phosphate, dipotassium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, sodium molybdate, sodium tungstate, and manganese sulfate; various vitamins; and amino acids.

[0055] The pH of the medium obtained by mixing the above components is in the range of 6.0 to 9.0, preferably 6.5 to 8.5, and more preferably 7.0 to 8.0.

[0056] The human dental pulp stem cells are cultured with the scaffold material at 36°C to 38°C, preferably 36.5°C to 37.5°C, under conditions of 1% to 25% O2 and 1% to 15% CO2.

[0057] The pharmaceutical composition of the present invention may be prepared by freezing human dental pulp stem cells together with a scaffold (i.e., by freezing a scaffold containing human dental pulp stem cells). In this case, a sufficient amount of human dental pulp stem cells may be added to the scaffold and cultured for approximately 24 to 48 hours before freezing, or human dental pulp stem cells may be added to the scaffold and expanded for 3 to 6 days, preferably 5 to 10 days, until the desired cell number is reached, and then frozen.

[0058] The pharmaceutical composition of the present invention may be provided as a kit containing human dental pulp stem cells and a scaffold material separately. In this case, prior to application to a patient, human dental pulp stem cells may be added to the scaffold material, cultured for the required time, for example, 24 to 48 hours, and then applied directly to the bone defect site (fracture site or osteonecrosis site). The human dental pulp stem cells included in the kit may be frozen or unfrozen. The kit may also contain other components necessary for preparing the pharmaceutical composition and applying (transplanting) the pharmaceutical composition.

[0059] During freezing, a cryoprotectant may be added to the culture medium. Examples of cryoprotectants that can be used include dextran, dimethyl sulfoxide, ethylene glycol, propylene glycol, sericin, glycerol, serum, and human serum albumin. Commercially available cryoprotectants may also be used.

[0060] 3. Method for preventing or treating intractable bone defects, and method for regenerating bone tissue The present invention also provides a method for preventing or treating intractable bone defects, comprising administering to a subject human dental pulp stem cells and a porous scaffold having osteoinductive ability. The method may comprise culturing human dental pulp stem cells together with a porous scaffold having osteoinductive ability, and administering (transplanting or injecting) the resulting mixture to a subject.

[0061] The subject of transplantation or injection is a mammal (human, cow, pig, monkey, mouse, rat, sheep, goat, etc.), preferably a human.

[0062] The human subject of administration (transplantation or injection) is not particularly limited, but is preferably an infant, a child, or an adult, and adults also include elderly people aged 65 or older. Furthermore, the human subject of administration may be, for example, a person with acquired impaired bone repair function due to trauma, fatigue, illness (e.g., caisson disease or cancer bone metastasis, including idiopathic cases), drug side effects (e.g., bone resorption inhibitors or steroid drugs), alcohol intake, or the like, or a person with osteoporosis or a decreased number of osteoprogenitor cells or a decreased proliferation or differentiation ability of osteoprogenitor cells due to aging, circulatory disorders, radiation exposure, or the like.

[0063] A scaffold containing transplanted human dental pulp stem cells can promote bone repair in bone defects, particularly bone repair (bone fusion) in fractures or osteonecrosis where healing progress is delayed. Furthermore, a scaffold containing transplanted human dental pulp stem cells can prevent delayed healing in fractures or improve delayed healing in fractures. Furthermore, a scaffold containing transplanted human dental pulp stem cells can prevent osteonecrosis or improve bone repair in osteonecrosis. Furthermore, a scaffold containing transplanted human dental pulp stem cells can prevent pseudoarthrosis in fractures. Furthermore, a scaffold containing transplanted human dental pulp stem cells can regenerate bone tissue, including cancellous bone, in bone defects, enabling the prevention or treatment of intractable bone defects.

[0064] Furthermore, the scaffold containing transplanted human dental pulp stem cells enhances the expression of genes involved in angiogenesis and genes involved in osteoblast formation in bone defects, thereby regenerating bone tissue and enabling the prevention or treatment of intractable bone defects. Examples of genes involved in angiogenesis include endothelin receptor genes, receptor activation-regulating protein genes, and interferon-induced transmembrane protein genes. Examples of genes involved in osteoblast formation include interferon-responsive genes.

[0065] Endothelin receptors include type A and type B. Receptor activation regulatory protein genes include RAMP1, RAMP2, and RAMP3. Interferon response genes include Mx and IRF genes.

[0066] The present invention also provides a method for regenerating bone tissue, including cancellous bone, in an intractable bone defect, which comprises administering to a subject human dental pulp stem cells and a porous scaffold having osteoinductive ability. The method may comprise culturing human dental pulp stem cells together with the porous scaffold having osteoinductive ability, and administering (implanting or injecting) the scaffold to a subject.

[0067] The present invention also provides a method for regenerating bone tissue accompanied by angiogenesis in intractable bone defects, which comprises administering to a subject human dental pulp stem cells and a porous scaffold having osteoinductive ability. The method may comprise culturing human dental pulp stem cells together with the porous scaffold having osteoinductive ability, and administering (implanting or injecting) the resulting material to a subject.

[0068] In the above-mentioned method for preventing or treating intractable bone defects and method for regenerating bone tissue, the scaffold material, human dental pulp stem cells, cell culture method, etc. used are all as described in 1 and 2.

[0069] The present invention will be specifically explained below with reference to examples, but the present invention is not limited to these examples.

[0070] Example 1. Preparation of an intractable bone defect model In order to reproduce a state in which bone marrow or periosteum stem cells are reduced or their proliferation and differentiation capabilities are impaired, rats were irradiated to reduce the number of bone marrow-, periosteum-, and muscle-derived stem cells, and an intractable bone defect model rat was prepared.

[0071] Sixteen-week-old Sprague Dawley rats (SD rats, CLEA Japan) were irradiated with a single dose of 20 Gy of X-rays (Faxitron X-ray CP-160) on the left tibia (the area other than the irradiated area was covered). Four weeks after irradiation, rats that had lost their hair naturally at the irradiated site were used to create bone defect models using the following procedure.

[0072] Under abdominal anesthesia, the left and right tibias of rats were shaved and disinfected with isodine solution. The skin was then incised and a 3 mm diameter bone defect was created with a drill at the exposed tibial shaft (approximately 3 mm distal to the tibial surface of the knee joint). The incision was then sutured, and the bone repair status of the left and right bone defects was monitored over time using micro-CT at 0 weeks (when the bone tunnel was created), 4 weeks, and 8 weeks after surgery.

[0073] Bone repair was observed over time in the non-irradiated right tibia, and the bone tunnel had almost spontaneously repaired by 8 weeks after treatment, whereas no bone repair was observed in the irradiated left tibia (n = 6). These results confirm that the irradiated rats prepared in this example are useful as a rat model that reflects the state of intractable bone defects due to a reduced natural healing capacity. While a temporary bone defect can be created by cauterizing the periosteum instead of radiation, the periosteal cauterization method allows for the supply of stem cells from the bone marrow, making the radiation-irradiated model established in this example useful as a model that more closely reflects the state of intractable fractures, a problem addressed by this invention.

[0074] Example 2. Verification of the bone healing promoting effect of dental pulp stem cells in a model of intractable bone defects Using SD rats that had been irradiated on both tibiae (other areas were shielded with lead plates) using the method described in Example 1, the bone healing promoting effect of a combination of human deciduous tooth-derived dental pulp stem cells (SHED) and ReFit (HOYA Technosurgical), a scaffold made of hydroxyapatite and collagen, was verified.

[0075] 2-1. Cell preparation Human deciduous tooth-derived dental pulp stem cells (Kidswell Bio) were put to sleep and then cultured in MesenCult (Stemcell Technologies) (MesenCult-hPL medium) containing 10% hPL (human platelet lysate). After 6-10 passages, these were used to prepare the next scaffold and cells.

[0076] 2-2. Preparation of scaffold and cells ReFit was hollowed out with a 2.5 mm diameter biopsy punch (height 3.5 mm) and placed in a 96-well plate at one well. 5 x 10 SHED prepared in 2-1 was placed in each well. 5 The cells were seeded at 50 μl / well (scaffold + SHED). As a control, an equal number of wells containing only ReFit were prepared, to which Mesencult-hPL was added. These were used in the transplantation experiment. These procedures were performed in a sterile environment.

[0077] Nine male SD rats were used in this experiment, which were irradiated in both tibiae at 16 weeks of age and kept until 20 weeks of age. Bone holes 3 mm in diameter and 3 mm deep were created in both tibiae of the rats in the same manner as in Example 1.

[0078] The control group was implanted into the bone tunnel of the right tibia with only the scaffold prepared in 2-2, and the left tibia with the scaffold prepared in 2-2 plus SHED. After implantation, the bone tunnel was covered with 50 μL of 2% high-purity alginate gel (UPALgel, Mochida Pharmaceutical). The fascia and skin were then sutured. The rats were administered gentamicin 8 mg / kg IP during surgery and the day after surgery to prevent infection.

[0079] 2-4. Confirmation of bone healing effect The healing status at the left and right surgical sites was observed longitudinally under anesthesia using micro-CT at 0, 2, 4, 6, and 8 weeks after surgery (2-3). The time-dependent bone repair process is shown in Figure 1.

[0080] In addition, based on the CT image data, the bone hole coverage rate (repair rate) at each time point was quantified using RATOC's image analysis software TRI / BON. The bone hole coverage rate was calculated as the degree to which the 3mm diameter hole was covered at each time point immediately after surgery (Figure 2). From 4 weeks after implantation, a significant increase in bone hole coverage rate was observed on the SHED implant side compared to the control side.

[0081] Furthermore, 8 weeks after surgery, the left and right tibiae were harvested for histological examination (Figures 3A and 3B). After perfusion fixation in 4% PFA, the excised tibiae were fixed in 4% PFA for another day and then decalcified in Morse's solution for 7–10 days. They were embedded in paraffin and thinly sectioned. The sections were stained with hematoxylin and eosin (HE) and examined under a light microscope.

[0082] On the control side, new bone formation was observed near the bone tunnel and deep within, but residual ReFit and surrounding scar tissue were observed in the center of the bone tunnel. Empty lacunae (small bone cavities lacking osteocytes) were observed at the edge of the distal bone defect, and necrotic bone was not remodeled, with poor new bone formation (Figure 3A).

[0083] On the scaffold + SHED side, bone formation was observed in the proximal and deep parts of the bone tunnel. Although there was scar tissue in the center of the bone tunnel, there was little ReFit remnant, and abundant blood vessels were observed morphologically. Good new bone formation was also observed at the distal end of the bone tunnel (Figure 3B).

[0084] These results suggest that SHED significantly promotes healing of refractory bone defects when combined with a scaffold.

[0085] Example 3. Comparison of scaffold materials Combinations of various scaffold materials with dental pulp stem cells were investigated. Water absorption and cell distribution within the scaffolds were measured for ReFit (HOYA Technosurgical), a composite of hydroxyapatite and collagen, Superpore (HOYA Technosurgical), a β-tricalcium phosphate, and Grafton Matric Strips (Medtronic), a demineralized bone matrix.

[0086] 3-1. Water absorption of the scaffold Each scaffold was punched with a φ2.5mm x 7mm biopsy punch and the water absorption was measured. The average water absorption of each scaffold is shown in Table 1.

[0087]

[0088] 3-2. Observation of cell distribution within the scaffold First, to visualize the dental pulp stem cells engrafted in each scaffold, the dental pulp stem cells were labeled using the following procedure.

[0089] Human deciduous tooth-derived dental pulp stem cells cultured in the same manner as in 2-1 of Example 2 were sedimented by centrifugation (300 G, 5 min, RT) and the supernatant was removed. MesenCul™ hPL Medium (Stemcell Technology) was added and the cells were cultured at a concentration of 1.0 x 10 5 The resulting solution was dispensed into 1.5 mL microtubes.

[0090] 500 μL of cell staining dye (40 μL of Calcein-AM solution (DOJINDO) stock solution added to 20 mL of PBS) was added to the microtube and incubated at 37°C for 15-30 minutes. After washing twice with PBS, the cells were diluted with MesenCult-hPL Medium to 3.0 × 10 5 The cells were adjusted to a concentration of 1000 cells / ml and seeded onto a 96-well plate.

[0091] Next, each scaffold (cut out with a biopsy punch) was placed vertically into the cells in the wells prepared in this way. After 15 minutes of incubation, the number of cells adhering to each scaffold was counted, demonstrating that all scaffolds adsorbed cells (Figure 4). Furthermore, the scaffolds were observed using three-dimensional imaging under a fluorescent microscope, and the number of cells on the side opposite the scaffold that contacted the cell suspension in the well was counted. This confirmed that SHED cells were distributed in each scaffold. Among the scaffolds used in this experiment, ReFit was able to distribute the most SHED cells deep into the scaffold.

[0092] 3-3. Examination of cell engraftment rate in the carrier Human deciduous tooth-derived dental pulp stem cells (SHED) cultured in the same manner as in 2-1 of Example 2 were sedimented by centrifugation (300 G, 5 min, RT) to remove the supernatant, and MesenCult-hPL Medium (Stemcell Technology) was added to the carrier. 6 Each scaffold material (punched with a biopsy punch) was placed vertically in a well of a 96-well plate, and 2x10 SHED cells were added. 5 The cells were seeded at 100 μL / well and cultured in a CO 2 incubator.

[0093] Fifteen minutes after seeding, each scaffold was removed from the well and transferred to a tube containing 2 ml of Cellartis MSC Xeno-Free Culture Medium. The ATP activity in the supernatant was measured using the Cell titer GRO 2.0 assay (Promega) to estimate cell number.

[0094] Similarly, one hour after seeding with SHED, each scaffold was removed from a different well, and the cell number was measured using Cell titer GRO 2.0 assay (Promega).

[0095] The engraftment rate of SHED was good for all scaffolds, and theoretically, almost all cells were distributed within the scaffolds 1 hour after seeding (Figure 5).

[0096] Example 4. Preparation of dental pulp stem cells and scaffold material A 2.5 × 2.5 × 3.5 mm piece of ReFit (HOYA Technosurgical) was placed per well in a 96-well plate (suspension culture plate), and 1 × 10 human deciduous tooth-derived dental pulp stem cells (SHED) were added. 6 The cells were seeded into each well containing ReFit and cultured for 12 hours in a CO2 incubator at 37°C. After adhesion, the cells were transferred to a 6-well plate containing MesenCult+hPL medium and cultured for 2 days. The cultured scaffold and SHED were transplanted into a severely immunodeficient (SCID) rat (14-15 weeks old) model of a difficult-to-heal bone defect, in which a bone tunnel had been created as in Example 2. Bone repair was observed as in Example 2.

[0097] Example 5. Verification of the bone healing promoting effect of dental pulp stem cells in an immunodeficiency model with intractable bone defects Using rats that were irradiated on both tibiae (other areas were shielded with lead plates) in the same manner as in Example 1, the bone healing promoting effect of combining human deciduous tooth-derived dental pulp stem cells (SHED) or bone marrow-derived stem cells (BMMSC) (Promocell) with ReFit (HOYA Technosurgical), a scaffold made of hydroxyapatite and collagen, was verified and compared.

[0098] In this experiment, to properly evaluate the cell function of SHED and BMMSC in the xenograft, SCID rats were irradiated to reduce the number of bone marrow-, periosteum-, and muscle-derived stem cells, creating an immunodeficient, intractable bone defect model rat.

[0099] 5-1. Cell preparation Human deciduous tooth-derived dental pulp stem cells (Kidswell Bio) were put to sleep and cultured in MesenCult-hPL (Stemcell Technologies). Cells passaged 6-10 times were used for the preparation of the next scaffold and cells. For the preparation of BMMSCs (Promocell), BMMSCs were put to sleep and cultured in Mesenchymal Stem Cell Growth Medium 2 (Takara). Cells passaged 6-10 times were used for the preparation of the next scaffold and cells.

[0100] 5-2. Preparation of scaffold and cells ReFit was hollowed out with a 2.5 mm diameter biopsy punch (height 3.5 mm) and placed in a 96-well plate at one cell per well. 5x10 SHED or BMMSC prepared in 2-1 were then added to the wells. 5 The scaffolds were seeded with 50 μl of cells / 50 μl (scaffold + SHED, scaffold + BMMSC) and incubated at 37°C / CO for 6 hours. 2 After culturing in an incubator, the cells were transferred to a 6-well plate containing 2.5 ml of culture medium and cultured for 2 days. An equal number of wells containing only ReFit were prepared as controls, and Mesencult-hPL medium was added to these wells and treated in the same manner. These wells were used in the transplantation experiments. These procedures were carried out in a sterile environment.

[0101] 5-3. Preparation of Bone Defect Model Sixteen-week-old SCID rats (F344-Il2rgem1Iexas, NBRP) were irradiated with a single dose of 20 Gy of X-rays (Faxitron X-ray CP-160) on both tibiae (irradiated areas were covered). Four weeks after irradiation, in rats where hair loss had occurred at the irradiated sites, bone holes 3 mm in diameter and 3 mm deep were created in both tibiae in the same manner as in Example 1 to prepare bone defect models.

[0102] 5-4. Cell transplantation into bone defect model The scaffold prepared in 5-2 alone was transplanted into the bone tunnel of the right tibia as a control group, while the scaffold + SHED or scaffold + BMMSC prepared in 5-2 was transplanted into the left tibia. The fascia and skin were then sutured. The rats were administered gentamicin 8 mg / kg IP during surgery and the day after surgery to prevent infection. Nine rats were created in the scaffold + SHED group, and six in the scaffold + BMMSC group, and subsequent verification was performed.

[0103] 5-5. Confirmation of bone healing effect After cell transplantation, the bone repair process was observed using micro-CT as in 2-4 of Example 2 (Figure 6: SHED(-) and BMMSC(-): control group transplanted side, SHED: scaffold + SHED transplanted side, BMMSC: scaffold + BMMSC transplanted side), and the bone hole coverage rate was calculated (SHED: average value of scaffold + SHED transplanted side, BMMSC: average value of scaffold + BMMSC transplanted side, SHED(-) and BMMSC(-): average value of scaffold only transplanted side) (Figure 7).

[0104] As a result, there was a clear difference in bone healing effect between the scaffold + SHED transplant side ("SHED") and the scaffold + BMMSC transplant side ("BMMSC"), and it was confirmed that the bone healing effect was significantly higher on the scaffold + SHED transplant side than on the side where only the scaffold was transplanted (Figures 6 and 7).

[0105] No significant bone repair effect was observed on the side where the scaffold + BMMSCs were implanted compared to the side where only the scaffold was implanted.

[0106] Example 6. Gene Ontology enrichment analysis (GO analysis) To verify the differences in bone repair effects between scaffold + SHED, scaffold + BMMSC, and scaffold only, as seen in Example 5, at the gene expression level, GO analysis was performed using the following method.

[0107] In the same manner as in Example 5, transplant components consisting of scaffold + SHED (SHED group), scaffold + BMMSC (BMMSC group), and scaffold only (control group) were prepared and implanted into bone defects formed in the femur of a SCID rat model of refractory bone defects similar to those in Example 5.

[0108] Two weeks after implantation, RNA extracted from the implant site tissue was analyzed using relative RNA abundance (calculated using histograms in histograms and stringtie assembly) to identify genes significantly altered between the SHED and control groups or between the BMMSC and control groups. These genes were identified as having higher expression levels in the SHED or BMMSC groups compared to the control group (UP DEG List) and lower expression levels in the SHED or BMMSC groups compared to the control group (DOWN DEG List). GO analysis was performed using Metascape on the UP DEG List and DOWN DEG List.

[0109] The SHED group showed increased expression of genes involved in angiogenesis and interferon-responsive genes, which are involved in osteoblast formation, but not in BMMSCs. Genes involved in angiogenesis that were upregulated in the SHED group but not in BMMSCs included Lama5 (laminin α5), Mcp-5 (Ccl12), Nfatc4, Sox18, Shb (SH2 domain-containing adaptor protein B), Cav1, Them100 (transmembrane protein), Fosl1, Nos3, Ehna1, Gja4 (gap junction protein α4), and Ifitm3. Interferon-responsive genes that were upregulated in the SHED group but not in BMMSCs included Mx1, Mx2, and Irf7. It is thought that in bone defects, SHED promotes angiogenesis, leading to the accumulation of mesenchymal stem cells and periosteal cells from the surrounding tissue, which differentiate into osteoblasts, thereby directly promoting bone formation through intramembranous ossification.

[0110] On the other hand, the BMMSC group showed increased expression of genes involved in chondrogenesis and genes related to endochondral bone differentiation, suggesting that a bone regeneration pathway may be occurring in bone defects, leading to bone formation via cartilage differentiation. Genes related to chondrogenesis and endochondral bone differentiation that were increased in the BMMSC group include Acan, Pthlh, Matn3, Snorc, Col11a1, and Col10a1.

[0111] In the control group, muscle gene expression was significantly increased. Specifically, the expression of muscle genes Myl11, Tnnt3, Pgam2, Cav3, Tnni2, Chrne, Acta1, Myl1, Mb, Atp2a1, Actn3, Tnnc1, Myoz2, Tnnc2, Asb2, Myh4, Stac3, Trim72, Myoz1, Tcap, Jsrp1, Myh2, Cacnb1, Trdn, Des, Kcnj11, Mybpc2, Casq1, and Actn2 was significantly increased. This suggests that fibrosis may be occurring due to myofibroblast proliferation in the control group. This increase in gene expression was not observed in the SHED or BMMSC groups. Furthermore, the control group did not exhibit the increased expression of genes directly involved in bone formation, as observed in the SHED or BMMSC groups.

[0112] According to the present invention, it becomes possible to regenerate bone tissue including cancellous bone, and to prevent or treat intractable bone defects.

[0113] All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety.

Claims

1. A pharmaceutical composition for preventing or treating intractable bone defects, comprising human dental pulp stem cells and a porous scaffold having bone inductive ability.

2. The pharmaceutical composition according to claim 1, wherein the human dental pulp stem cells are human deciduous dental pulp stem cells.

3. The pharmaceutical composition of claim 1, wherein the scaffold is biodegradable.

4. The pharmaceutical composition according to claim 1, wherein the scaffolding material is composed of any one selected from calcium phosphates, collagen, bioabsorbable polymers, glucosamines, demineralized bone, and complexes consisting of two or more of these.

5. The pharmaceutical composition described in claim 4, wherein the calcium phosphates are one or a combination of two or more selected from the group consisting of dicalcium phosphate, tricalcium phosphate, tetracalcium phosphate, octacalcium phosphate, hydroxyapatite, carbonate apatite, and fluoroapatite; the collagen is one or a combination of two or more selected from the group consisting of type I collagen, type II collagen, type III collagen, and synthetic collagen; the bioabsorbable polymer is one or a combination of two or more selected from the group consisting of polylactic acid polymer, polyglycolic acid polymer, and polylactic acid / glycolic acid polymer; the glucosamines are glucosamine, N-acetylglucosamine, or a combination thereof; and the demineralized bone is derived from mammalian bone; 6. The pharmaceutical composition of claim 1, wherein the scaffold has a porosity of 50% or more.

7. The pharmaceutical composition according to claim 1, wherein the pore size of the scaffold is 20 to 700 μm.

8. The pharmaceutical composition according to claim 1, wherein the scaffolding material is composed of any one selected from calcium phosphates having a Ca / P ratio of 1.0 to 2.0, collagen, and a complex consisting of two or more of these.

9. The pharmaceutical composition according to claim 1, wherein the scaffold material is selected from the group consisting of hydroxyapatite, β-TCP, collagen, and a complex consisting of two or more of these.

10. The pharmaceutical composition according to claim 1, wherein the scaffold material is a composite of hydroxyapatite and collagen.

11. The pharmaceutical composition of claim 10, wherein the scaffold comprises hydroxyapatite and collagen in a weight ratio of 90:10 to 50:

50.

12. The pharmaceutical composition according to claim 1, which is prepared by culturing human dental pulp stem cells together with a scaffold material.

13. Scaffolding 100mm 3 At least 1x10 per 5 The pharmaceutical composition of claim 1 , comprising human dental pulp stem cells.

14. The pharmaceutical composition according to claim 1, wherein the intractable bone defect is any one selected from femoral fracture, vertebral fracture including vertebral compression fracture, hip fracture, limb fracture, femoral head necrosis, and pelvic fracture.

15. The pharmaceutical composition according to claim 1, wherein the prevention or treatment of refractory bone defects is the prevention or treatment of delayed healing, osteonecrosis, or prevention of false joints.

16. The pharmaceutical composition according to any one of claims 1 to 15, which regenerates bone tissue including cancellous bone in a bone defect area.